The Single-Arm, Phase II Study of mirvetuximab soravtansine study, a phase II single-arm trial, included 106 FRα-high patients with platinum-resistant epithelial ovarian cancer who had received 1 to 3 prior therapies, including bevacizumab.[15] The primary endpoint, confirmed ORR by the investigator, was 32.4%, with a median duration of response of 6.9 months. This evidence concerns the gene FOLR1 and ovarian carcinoma.